Loading stock data…
ACIU
$2.98-0.05 (-1.65%)
Market ClosedLast close May 1
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AC Immune SA in the Healthcare sector is trading at $2.98. The stock is currently 26% below its 52-week high of $4.00, remaining 2.8% above its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why ACIU maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.98
Potential Upside
5%
Whystock Fair Value$3.13
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$311.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.63
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-163.27%
Volume
Today's trading volume
457,821
Recent News
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates
AC Immune (ACIU) delivered earnings and revenue surprises of +5.00% and +42.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Leerink Says AC Immune (ACIU) Eli Lilly Tau Program Amendment Is Great News
AC Immune SA (NASDAQ:ACIU) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 7, 2026, Leerink analyst Marc Goodman said AC Immune SA (NASDAQ:ACIU) amending its collaboration with Eli Lilly for the Morphomer Tau program is “great news,” highlighting continued interest in targeting intracellular Tau for early Alzheimer’s prevention. […]
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.
April 2026's Most Promising Penny Stocks
The U.S. market has experienced a notable climb, rising 1.2% in the last week and 33% over the past year, with earnings projected to grow significantly in the coming years. In such a robust market climate, identifying stocks with strong financial foundations is crucial for investors seeking value beyond established names. Penny stocks, often representing smaller or newer companies, remain an intriguing investment area despite their somewhat outdated label; they can offer surprising...